Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
faecal bacteriotherapy solution
- Development stage
- Phase 4
- Lead developer
- Charles University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Faecal bacteriotherapy solution (FBT) is an investigational microbiome-based therapeutic consisting of a standardized 350 ml preparation of mixed transplantate derived from the feces of seven healthy donors. It is administered via rectal enema to restore intestinal microbial diversity in patients whose gut microbiome has been disrupted by antibiotic use. Developed in the context of academic research at Charles University and supported by the Donatio Intensivistam Endowment Fund, FBT is primarily investigated for the treatment of postantibiotic diarrhoea in critically ill patients, including those with Clostridioides difficile infection. Unlike commercial live biotherapeutic products, this solution is a complex community of donor gut microorganisms rather than a single-strain or defined-consortium product.
- Other names
- faecal microbiota transplantationFMT solutionstandardised mixed transplantate
Beyond the preview
Go deeper on faecal bacteriotherapy solution.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on faecal bacteriotherapy solution.